Clinical Trials Logo

Clinical Trial Summary

Irisin is an exercise-mimetic myokine secreted by skeletal muscle. Compelling evidence in animal models and humans showed that Irisin prevents onset of musculoskeletal atrophy and its low serum levels are predictive of sarcopenia. The investigators evaluated the levels of irisin in patients affected by an hereditary motor and sensory neuropathy, namely Charcot-Marie-Tooth disease (CMT), in order to investigate possible key determinants of their muscle quality and possibly prevent the progressive distal weakness and muscle atrophy.


Clinical Trial Description

Currently, there are no effective treatment approaches for CMT other than treating symptoms with medications such as nonsteroidal anti-inflammatory drugs that provide relief of lower back or leg pain. Except for the most severe cases in which orthopedic surgery is recommended to correct pes cavus and/or spine deformities, rehabilitative management of patients with CMT has shown that physical activity can provide a moderate increase in muscle strength and musculoskeletal function, improving activities of daily living. Benefits of exercise on the musculoskeletal system are widely recognized as primary non-pharmacologic intervention for several diseases. The positive outcome of physical activity is achieved not only by the mechanical load applied on the musculoskeletal system, but also via biochemical signals, the myokines, secreted during contraction that act locally or systemically on several body districts. Among these, Irisin is a hormone-peptide synthesized from skeletal muscle performing key actions on the whole-body metabolism. In humans, the investigators have documented with several studies an existing positive association between circulating levels of Irisin and bone mineral density. Very recently, in muscle biopsies of older adult subjects, the investigators also observed that the expression of the Irisin precursor, the fibronectin type III domain-containing protein 5 (FNDC5), was positively associated with Irisin serum levels and osteocalcin mRNA expression in bone biopsies, indicating a strong correlation between healthy muscle and bone tissues. In humans, low levels of circulating Irisin have been found to be predictive of muscle weakness and atrophy, and Irisin has been identified as a sensitive molecular biomarker for sarcopenia in postmenopausal women. In addition, women older than 65 years undergoing a 12-week exercise program showed an increase in circulating Irisin and an improvement in isokinetic leg strength and grip strength compared with control women. Moreover, there was a positive correlation between Irisin levels with grip strength and leg strength in the exercise group, suggesting a causal relationship between improved muscle strength and increased Irisin concentration. Although numerous reports recommend increasing muscle strength in CMT patients to prevent progressive distal weakness and muscle atrophy, few studies have investigated the possible key determinants of muscle quality in these patients. Therefore, the aim of this study was to evaluate circulating Irisin levels in a population of 20 CMT patients as well the association of Irisin with biochemical parameters and muscle quality. In addition, the investigators compared these data with unpublished data previously obtained in healthy subjects. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04786522
Study type Observational
Source University of Bari
Contact
Status Completed
Phase
Start date November 2, 2019
Completion date December 30, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT06203093 - Charcot-Marie-Tooth Disease (CMT) Biological Sample Collection for iPSC Generation and Biobanking
Recruiting NCT03782883 - The Impact of Charcot-Marie-Tooth Disease in the Real World
Recruiting NCT02979145 - Charcot-Marie-Tooth Disease (CMT) Infant Scale (INC-6611) N/A
Terminated NCT03254199 - A Study to Assess the Safety and Effectiveness of FLX-787 in Subjects With Charcot-Marie-Tooth Disease Experiencing Muscle Cramps. Phase 2
Completed NCT02011204 - Study of Electrical Impedance Myography (EIM) in ALS N/A
Completed NCT00149045 - Follow up and Observation of Charcot Marie Tooth Disease in Families N/A
Recruiting NCT05011006 - NT-3 Levels and Function in Individuals With CMT
Recruiting NCT05902351 - Natural History Study for Charcot Marie Tooth Disease
Terminated NCT03943290 - Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX) Phase 2
Active, not recruiting NCT04762758 - Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients Phase 3
Completed NCT02788734 - Patient Reported Outcomes Measures (PROM) in Carpal Tunnel Therapies in Patients With Inherited Neuropathies N/A
Recruiting NCT02532244 - Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases
Terminated NCT05827419 - Hearing and Balance Disorders in Peripheral Neuropathy
Terminated NCT03124459 - Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Phase 2
Terminated NCT03810508 - A Natural History Study of Charcot-Marie-Tooth 4J (CMT4J)
Recruiting NCT04010188 - A Registered Cohort Study on Charcot-Marie-Tooth Disease
Completed NCT00271635 - Ascorbic Acid Treatment in CMT1A Trial (AATIC) Phase 2
Completed NCT03715283 - Change in MUNIX in Patients With CMT1A Undergoing a Home Ankle Strengthening Program Versus Standard of Care N/A
Completed NCT02001038 - Survey of Current Management of Orthopaedic Complications in CMT Patients N/A
Not yet recruiting NCT01289704 - Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program for Charcot−Marie−Tooth Neuropathy Type 1A (CMT1A) Phase 2/Phase 3